Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil added to pirfenidone for advanced idiopathic pulmonary fibrosis with probable group 3 pulmonary hypertension
MOH_2017-05-07_000258Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) comparing pirfenidone + sildenafil with pirfenidone + placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Relevant 6-minute walk distance decline definition. Started Jan 2017; status: active, not recruiting.
02
Drugs
sildenafilpirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on MOH_2017-05-07_000258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-07_000258.